Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + cisplatin + 5-fluorouracil + Endostar
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three chemotherapeutic agents—epirubicin, cisplatin, and 5-fluorouracil (5-FU)—with Endostar (recombinant human endostatin). Epirubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity. Cisplatin is a platinum-based compound that forms DNA crosslinks and induces apoptosis. 5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. Endostar is an antiangiogenic biologic agent developed in China; it inhibits tumor angiogenesis by blocking the VEGF/VEGFR2 pathway and normalizing tumor vasculature[1][4][7]. This combination aims to enhance antitumor efficacy by combining direct cytotoxic effects with inhibition of tumor blood vessel formation. It has been studied primarily in solid tumors such as non-small cell lung cancer (NSCLC) and other malignancies[3][8].
- Brand names
- Endostar
- Other names
- ECF + EndostarECF-Endostarepirubicin, cisplatin, and 5-fluorouracil plus Endostar
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on epirubicin + cisplatin + 5-fluorouracil + Endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + cisplatin + 5-fluorouracil + Endostar.